← Trials/Trial dossier/NCT05418907

ENTRAP

Unknown

Exendin PET/CT for Imaging of Paragangliomas

Exendin PET/CT for Paragangliomas

Lead sponsor

Radboud University Medical Center

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Detection rate of PGL's

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05418907

Org study ID2021-000194-93

Timeline

Milestones

Study start2022-06-01actual

Study first posted2022-06-14actual

Last update posted2023-12-08actual

Primary completion2024-12-01estimated

Study completion2024-12-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

patients with biochemically proven PGL

Inclusion criteria

•Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging

•No evidence of metastatic disease

•CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging)

•Scheduled for surgery

•Able to sign informed consent

Exclusion criteria

•Breast feeding

•Pregnancy or the wish to become pregnant within 1 month

•Calculated creatinine clearance below 40ml/min

•Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions)

•Age < 18 years

•Not able to sign informed consent

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

detection rate of PGL's using 68Ga-exendin-4 PET/CT

Time frame:1 year

threshold achievement, descriptive

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT

Time frame:After inclusion of the first 5 patients (up to 6 months)

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Silica-Coated Nanoparticles with a Core of Zinc, l-Arginine, and a Peptide Designed for Oral Delivery.
ACS applied materials & interfaces2020 Jan 8PMID31802658doi:10.1021/acsami.9b16104via pubmed acronym asset candidate
Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2009 May-Jun (year)PMID19454385doi:10.4158/EP09046.ORRvia pubmed acronym asset candidate

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.